October 2026 | HPA-Global Member & Partner News

The International Probiotics Association (IPA) has highlighted emerging scientific evidence examining the potential benefits and safety risks of administering probiotics to premature infants receiving care in neonatal intensive care units (NICUs).

In a recently shared article titled Probiotics and Infection in Preterm Infants: Benefits and Risks, IPA draws attention to an important clinical question: whether probiotics can help protect vulnerable premature infants against serious intestinal complications and infections without introducing additional health risks.

One of the principal areas of research involves necrotizing enterocolitis (NEC), a potentially life-threatening intestinal disease affecting premature infants. Clinical studies and systematic reviews have suggested that certain probiotic strains and combinations may reduce the incidence of NEC and, in some circumstances, mortality.

However, the evidence is not uniform across all probiotic formulations or patient populations. Researchers have also raised concerns about probiotic-associated sepsis, in which microorganisms contained in probiotic products enter the bloodstream and cause serious infections.

These risks are particularly important for extremely premature infants, whose immature immune systems and intestinal barriers make them especially vulnerable.

The U.S. Food and Drug Administration previously warned healthcare providers about potentially fatal infections associated with probiotic administration in premature infants. The agency has not approved any probiotic product as a drug or biological product for use in infants.

The American Academy of Pediatrics has likewise advised against routine, universal probiotic administration to premature infants, particularly those weighing less than 1,000 grams at birth, while recognizing that selected neonatal care centers may evaluate their use under carefully controlled clinical protocols.

The continuing research underscores the importance of strain-specific clinical evidence, rigorous manufacturing controls, product purity, microbial identification and appropriate medical supervision when considering probiotics for highly vulnerable populations.

What this means for the industry

The growing body of research surrounding neonatal probiotic applications represents both a significant scientific opportunity and an important regulatory challenge for the global probiotics industry.

For probiotic manufacturers and ingredient suppliers, the findings reinforce the need to move beyond generalized claims about beneficial bacteria and toward well-characterized, clinically validated strains supported by population-specific safety and efficacy data.

The research also highlights the importance of pharmaceutical-grade manufacturing standards, contamination prevention, strain traceability and appropriate regulatory pathways for products intended for medically vulnerable populations.

For companies developing probiotics for infant and children’s nutrition, the distinction between conventional consumer supplements and products intended for clinical use is especially important. Evidence supporting one application cannot automatically be extended to another.

Ultimately, the discussion reflects the industry’s broader evolution toward precision microbiome science, in which probiotic selection, product quality and the characteristics of the intended population are central to determining both potential benefits and risks.

Sources: International Probiotics Association (IPA), public LinkedIn update and article Probiotics and Infection in Preterm Infants: Benefits and Risks; U.S. Food and Drug Administration; American Academy of Pediatrics.

Original sources: IPA public LinkedIn company page | FDA safety communication | AAP clinical report.

About HPA-Global: If your company is active in the dietary supplement, functional food, ingredient, or health products industry and is not yet a member of HPA-Global, we invite you to consider joining the association. HPA-Global supports members with China and global market intelligence, marketing visibility, industry connections, and access to regulatory support for supplements, ingredients, and related health products in China, the EU, Japan, South Korea, and the U.S. For companies looking to expand internationally and stay ahead of market and regulatory changes, HPA-Global offers one of the best values in the industry. For more details, visit www.hpaglobal.org/connect.